Oncology Stakeholders Offer Niche Recommendations To US FDA, But Who Will Ultimately Get Their Way?
Advocates, industry give wish lists for changes to Office of Oncology Excellence, but Commissioner Scott Gottlieb will ultimately determine who gets what.
You may also be interested in...
Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.
Brad Thompson says that phone calls used in current informal process help sponsors understand Office of Combination Product’s thinking, and that a formalized process envision in the new draft guidance could make this dialogue more difficult.
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.